Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA approves Regeneron drug for generalized myasthenia gravis
00

FDA approves Regeneron drug for generalized myasthenia gravis

Nov 18, 2026

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) on November 18, 2026, marking the first siRNA therapy for generalized myasthenia gravis. Administered subcutaneously four times a year, Livsayis achieved a placebo-adjusted 2.3-point MG-ADL improvement in the Phase 3 NIMBLE trial. Concurrently, FDA approved AstraZeneca's weekly autoinjector Klygefa. Both C5-targeted treatments enter a competitive market alongside established therapies from argenx and UCB.

FDA approval and administration of Livsayis

  • ▪Regeneron said Livsayis is administered by subcutaneous injection once every three months, making it the longest dosing interval among FDA-approved generalized myasthenia gravis treatments
  • ▪The U.S. FDA approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) on November 18, 2026, for adult patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Mechanism and safety profile of Livsayis

  • ▪The FDA prescribing information for Regeneron's Livsayis includes a Boxed Warning for serious meningococcal infections and requires access through a restricted Risk Evaluation and Mitigation Strategy program
  • ▪Livsayis is a complement component factor 5 directed small interfering RNA therapeutic that degrades C5 messenger RNA to block C5 protein production

NIMBLE trial results for Livsayis

  • ▪In the Phase 3 NIMBLE trial, 76.6 percent of Livsayis-treated patients achieved at least a 3-point MG-ADL score improvement at week 24 compared to 44.1 percent for placebo
  • ▪In the Phase 3 NIMBLE trial, Livsayis demonstrated a placebo-adjusted 2.3-point improvement on the Myasthenia Gravis-Activities of Daily Living total score at 24 weeks

FDA approval and structure of Klygefa

  • ▪The FDA approved AstraZeneca and Alexion's Klygefa (gefurulimab-gaks) on November 16, 2026, as a once-weekly self-injected C5 inhibitor for adult anti-acetylcholine receptor positive gMG patients
  • ▪AstraZeneca's Klygefa is a dual-binding nanobody that combines an N-terminal albumin-binding domain with a C-terminal C5-binding domain to extend blood half-life and enable weekly dosing

PREVAIL trial results for Klygefa

  • ▪In the Phase 3 PREVAIL trial, Klygefa-treated patients achieved a 4.5-point QMG total score improvement at week 26 compared to a 2.4-point improvement for placebo
  • ▪In the Phase 3 PREVAIL trial of 260 patients, weekly Klygefa achieved a 1.6-point greater MG-ADL score reduction than placebo at week 26

Myasthenia gravis prevalence

  • ▪Myasthenia gravis affects approximately 85,000 people in the United States, causing abnormal anti-acetylcholine receptor antibodies to activate complement protein C5 and damage the neuromuscular junction
  • ▪An estimated 150 to 200 out of every million people worldwide have myasthenia gravis

Existing treatment landscape

  • ▪Projected prescription data through September 30, 2026, showed argenx's Vyvgart leading generalized myasthenia gravis patient starts with about 3,138 starts
  • ▪Existing C5-targeted generalized myasthenia gravis therapies include Alexion's Soliris and Ultomiris, argenx's Vyvgart, and UCB's Zilbrysq and Rystiggo

4 sources

The American Journal of Managed Care
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis | AJMC
View source article
BioSpace
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing - BioSpace
View source article
Tech Times
FDA Approves Klygefa for Weekly Myasthenia Gravis Self-Injection; Meningococcal Warning Unconfirmed
View source article
Reuters
US FDA approves Regeneron's drug for generalized myasthenia gravis | Reuters
View source article

Story comments

Loading comments…

Related entities

United StatesJapan

Related Projects

AstraZeneca

Topics

FDA drug approvalRisk evaluation & mitigation (REMS)Drug Policy, Pricing & ApprovalClinical trialsRare diseasesAutoimmune diseaseEuropean Union